IL112903A - GnRH antagonist peptides and their use in the preparation of a pharmaceutical composition - Google Patents

GnRH antagonist peptides and their use in the preparation of a pharmaceutical composition

Info

Publication number
IL112903A
IL112903A IL11290395A IL11290395A IL112903A IL 112903 A IL112903 A IL 112903A IL 11290395 A IL11290395 A IL 11290395A IL 11290395 A IL11290395 A IL 11290395A IL 112903 A IL112903 A IL 112903A
Authority
IL
Israel
Prior art keywords
preparation
pharmaceutical composition
gnrh antagonist
antagonist peptides
peptides
Prior art date
Application number
IL11290395A
Other languages
English (en)
Other versions
IL112903A0 (en
Original Assignee
Salk Inst For Biological Studi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22783633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL112903(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Salk Inst For Biological Studi filed Critical Salk Inst For Biological Studi
Publication of IL112903A0 publication Critical patent/IL112903A0/xx
Publication of IL112903A publication Critical patent/IL112903A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL11290395A 1994-03-18 1995-03-07 GnRH antagonist peptides and their use in the preparation of a pharmaceutical composition IL112903A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/210,627 US5506207A (en) 1994-03-18 1994-03-18 GNRH antagonists XIII

Publications (2)

Publication Number Publication Date
IL112903A0 IL112903A0 (en) 1995-06-29
IL112903A true IL112903A (en) 2000-07-26

Family

ID=22783633

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11290395A IL112903A (en) 1994-03-18 1995-03-07 GnRH antagonist peptides and their use in the preparation of a pharmaceutical composition

Country Status (11)

Country Link
US (1) US5506207A (hu)
EP (1) EP0804471A1 (hu)
JP (1) JPH10500397A (hu)
KR (1) KR970701730A (hu)
AU (1) AU681266B2 (hu)
CA (1) CA2185710A1 (hu)
HU (1) HU217552B (hu)
IL (1) IL112903A (hu)
NZ (1) NZ282315A (hu)
WO (1) WO1995025741A1 (hu)
ZA (1) ZA951930B (hu)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744450A (en) * 1991-03-14 1998-04-28 The Salk Institute For Biological Studies GnRH analogs
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5807983A (en) * 1995-12-28 1998-09-15 The Salk Institute For Biological Studies GNRH antagonist betides
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US5977302A (en) * 1997-11-20 1999-11-02 Ortho-Mcneil Pharmaceutical, Inc. Liquid phase process for the preparation of GnRH peptides
AU753540B2 (en) 1998-03-05 2002-10-24 Agouron Pharmaceuticals, Inc. Non-peptide GnRH agents
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
EP1778278B1 (en) * 2004-07-16 2014-05-21 Oakwood Laboratories L.L.C. Gonadotropin releasing hormone antagonists
AU2007235251B2 (en) * 2006-04-07 2013-02-07 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
JP5649825B2 (ja) 2007-01-31 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 安定化させたｐ５３ペプチドおよびその使用法
KR101525754B1 (ko) 2007-03-28 2015-06-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
TWI442932B (zh) * 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
WO2009137078A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
US20100215743A1 (en) * 2009-02-25 2010-08-26 Leonard Thomas W Composition and drug delivery of bisphosphonates
EP2424503B1 (en) 2009-05-01 2017-07-05 Ferring BV Composition for the treatment of prostate cancer
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
CN108570097A (zh) 2010-08-13 2018-09-25 爱勒让治疗公司 拟肽大环化合物
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
ES2617336T3 (es) 2010-10-27 2017-06-16 Ferring B.V. Procedimiento para la fabricación de degarelix y sus productos intermedios
US8802114B2 (en) 2011-01-07 2014-08-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
MX358886B (es) 2011-10-18 2018-08-31 Aileron Therapeutics Inc Macrociclos peptidomimeticos.
SG11201404648PA (en) 2012-02-15 2014-09-26 Aileron Therapeutics Inc Peptidomimetic macrocycles
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN104334182B (zh) 2012-06-01 2017-09-08 辉凌公司 制造地加瑞克
EP2914256B1 (en) 2012-11-01 2019-07-31 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
JP2017533889A (ja) 2014-09-24 2017-11-16 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
EP3294318A4 (en) 2015-03-20 2019-04-03 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444759A (en) * 1982-07-26 1984-04-24 The Salk Institute For Biological Studies GnRH Antagonists II
US4619914A (en) * 1983-03-10 1986-10-28 The Salk Institute For Biological Studies GNRH antagonists IIIB
US4652550A (en) * 1984-05-21 1987-03-24 The Salk Institute For Biological Studies GnRH antagonists VII
US5169932A (en) * 1989-10-30 1992-12-08 The Salk Institute For Biological Studies Gnrh analogs
US5296468A (en) * 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
IL101074A (en) * 1991-03-14 1997-09-30 Salk Inst For Biological Studi GnRH ANALOGS AND THEIR PREPARATION

Also Published As

Publication number Publication date
JPH10500397A (ja) 1998-01-13
HU9602550D0 (en) 1996-11-28
AU1938795A (en) 1995-10-09
ZA951930B (en) 1995-12-11
US5506207A (en) 1996-04-09
HUT74808A (en) 1997-02-28
CA2185710A1 (en) 1995-09-28
KR970701730A (ko) 1997-04-12
EP0804471A1 (en) 1997-11-05
WO1995025741A1 (en) 1995-09-28
AU681266B2 (en) 1997-08-21
NZ282315A (en) 1997-12-19
HU217552B (hu) 2000-02-28
IL112903A0 (en) 1995-06-29

Similar Documents

Publication Publication Date Title
IL112903A (en) GnRH antagonist peptides and their use in the preparation of a pharmaceutical composition
IL114578A0 (en) Amino purine-béta-D ribofuranuronamide derivatives their preparation pharmaceutical compositions containing them and their use
IL113844A (en) N-(alpha-ETHYLBENZYL)-3-HYDROXY-2-PHENYLQUINOLINE-4-CARBOXAMIDE AND ITS USE IN THE PREPARATION OF MEDICAMENTS
HUP0100149A3 (en) Antipicornaviral peptide derivatives pharmaceutical compositions comprising thereof and their use
IL116323A0 (en) Tachykinin antagonists their preparation and pharmaceutical compositions containing them
IL116512A0 (en) Cyclic peptides their preparation and pharmaceutical compositions containing them
EP0950665A4 (en) PHYSIOLOGICALLY ACTIVE MODIFIED PROTEINS AND DRUG COMPOSITIONS CONTAINING THEM
IL114925A0 (en) Glycinamide derivatives their preparation and pharmaceutical compositions containing them
HU9503624D0 (en) Use of p antagonist in pharmaceutical compositions
IL114407A0 (en) Novel peptides and pharmaceutical compositions comprising them
IL113484A0 (en) Viral proteins pharmaceutical compositions containing them their preparation and use
AU5650894A (en) Tachyquinine antagonists, their preparation and use in pharmaceutical formulations
ZA96240B (en) Novel peptides their preparation and use
ZA9811470B (en) Pharmaceutical compositions based on dalfopristine and on quinupristine and their preparation
IL117395A0 (en) Bicyclic compounds preparation thereof and use in pharmaceutical compositions
IL120239A0 (en) Macrocyclic peptides pharmaceutical composition containing them and their use
IL125262A0 (en) Synthetic peptides and pharmaceutical compositions comprising them
HRP970615B1 (en) Stabilized pharmaceutical compositions with quinupristine and dalfopristine base and their preparation
IL116658A0 (en) Peptides their preparation and use
ZA982952B (en) Pseudo-peptide compounds their preparation and use in pharmaceutical formulations
IL110954A (en) Pharmaceutical compositions comprising a retinoblastoma polypeptide or protein and methods for the preparation and use thereof
HUP9903619A3 (en) Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist
IL113415A0 (en) Dihydrodibenzoquinolinediones their preparation and use and pharmaceutical compositions containing them
IL114161A0 (en) Amido- quinoxalinediones pharmaceutical compositions containing them and their use
NZ234011A (en) Peptide bombesin antagonists and pharmaceutical compositions

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees